Cocktail of hormones can reduce the risk of breast cancer in those most at risk
| Home Health IndexHealth News & Fitness GuideCommentsPosts | ||
| Health IndexHealth News & Fitness Guide | CommentsPosts | |
Follow Us On TwitterMy TweetsTwitter Followers HealthIndexUK on Twitter Follow @HealthIndexUK 25 people follow HealthIndexUK The_Gym_ Surgical victoria SteveMov TalkMedi M_RFitne SimplySu healthbl Pages Advertising Contact Us Privacy Policy Recent Posts Lets talk about the Elephant in the GP Waiting Room! Experts tell us its time to ditch our morning fruit juice Public Health England urges standardisation of cigarette packaging Dry January aims to cut alcohol consumption in the New Year Britain lagging behind the rest of Europe for cancer survival rates Subscribe to Blog via Email Enter your email address to subscribe to this blog and receive notifications of new posts by email.
| « Coronary heart disease symptoms Advantages of stairlifts and rise and recline chairs » Cocktail of hormones can reduce the risk of breast cancer in those most at risk Research has shown that a cocktail of hormone treatments can reduce the incidence of breast cancer in women who are currently at the risk of getting the disease. Tamoxifene, is currently being used for the post-surgery management of the disease, while Raloxifene, Lasofoxifene, and Arzoxifene, are used for the management of Osteoporosis. According to the study, based on the medical records of 83,000 women who are on the program, the drugs have reduced the incidence of breast cancer by 38%. The study involved the monitoring of the subjects under the drug for 5 years, and then stopping its administration and observing them for another 5 years. The initial result after 5 years, showed a 42% reduction in the incidence of breast cancer, and another 25% reduction was observed after the treatment was stopped. There was no effect on the fatalities related to the disease, or on the incidence of non-oestrogen related breast cancer. The drugs are selective oestrogen receptor modulators (SERMS) and work by stimulating Oestrogen-sensitive molecules in the body. Not all stimulate the cells, and Raloxifene blocks the stimulating effect in breast tissue, but stimulates the effects in the bones. Jack Cuzick, from Queen Mary University of London, led the study, and reported to The Lancet medical journal that the results were very encouraging, and created a way of popularizing the treatment amongst women who at high risk of getting the disease, just as statins and blood pressure-reduction drugs were used to stave off heart attacks, and stroke. In the UK, Tamoxifene has not yet been given the green-light as a treatment for breast cancer. The regulator, The National Institute for Health and Clinical Excellence (NICE), is tasked with scrutinizing the effectiveness of new treatments. It has recommended that the drug, Tamoxifene, be given to women who are at a high risk of developing breast cancer, on a provisional basis. Later in the year, NICE will give it final recommendations on the administration of the drug. The study also showed that the four drugs were able to reduce the clotting of blood significantly. However, Tamoxifene was found to increase the development of womb cancer. No related posts. May 2nd, 2013 | Tags: breast cancer, Drugs for breast cancer, reducing the risks of breast cancer | Category: Alternative Treatments, Cancer, Drugs Leave a Reply Cancel Name (required) Mail (will not be published) (required) Website You can use these HTML tags | Most PopularToxocariasis is a serious risk from dog feaces Categories Alcohol Allergies Alternative Treatments Alzheimers Asthma Autism Cancer Care for the elderly Cosmetic Surgery Deafness Dental Depression Diabetes Diet Drugs Eyes Fashion Fertility Fitness Fundraising General Gyms Health Products Hearing Heart disease HIV Insurance Medical Conditions Medical News Medical Research Mental Health MRSA NHS Psoriasis Public Health Republic Skin cancer Smoking Tuberculosis Vitamins |
| Copyright © 2014 Health IndexPowered by WordPress & the Atahualpa Theme by BytesForAll. Discuss on our WP Forum This site uses cookiesNo problemMore info |
Health IndexHealth News & Fitness Guide CommentsPosts
Health Index
Health News & Fitness Guide
Follow Us On Twitter
Twitter Followers
Pages
Recent Posts
- Lets talk about the Elephant in the GP Waiting Room!
- Experts tell us its time to ditch our morning fruit juice
- Public Health England urges standardisation of cigarette packaging
- Dry January aims to cut alcohol consumption in the New Year
- Britain lagging behind the rest of Europe for cancer survival rates
Subscribe to Blog via Email
Enter your email address to subscribe to this blog and receive notifications of new posts by email.
Cocktail of hormones can reduce the risk of breast cancer in those most at risk
Research has shown that a cocktail of hormone treatments can reduce the incidence of breast cancer in women who are currently at the risk of getting the disease. Tamoxifene, is currently being used for the post-surgery management of the disease, while Raloxifene, Lasofoxifene, and Arzoxifene, are used for the management of Osteoporosis.
According to the study, based on the medical records of 83,000 women who are on the program, the drugs have reduced the incidence of breast cancer by 38%. The study involved the monitoring of the subjects under the drug for 5 years, and then stopping its administration and observing them for another 5 years.
The initial result after 5 years, showed a 42% reduction in the incidence of breast cancer, and another 25% reduction was observed after the treatment was stopped. There was no effect on the fatalities related to the disease, or on the incidence of non-oestrogen related breast cancer.
The drugs are selective oestrogen receptor modulators (SERMS) and work by stimulating Oestrogen-sensitive molecules in the body. Not all stimulate the cells, and Raloxifene blocks the stimulating effect in breast tissue, but stimulates the effects in the bones.
Jack Cuzick, from Queen Mary University of London, led the study, and reported to The Lancet medical journal that the results were very encouraging, and created a way of popularizing the treatment amongst women who at high risk of getting the disease, just as statins and blood pressure-reduction drugs were used to stave off heart attacks, and stroke.
In the UK, Tamoxifene has not yet been given the green-light as a treatment for breast cancer. The regulator, The National Institute for Health and Clinical Excellence (NICE), is tasked with scrutinizing the effectiveness of new treatments. It has recommended that the drug, Tamoxifene, be given to women who are at a high risk of developing breast cancer, on a provisional basis.
Later in the year, NICE will give it final recommendations on the administration of the drug. The study also showed that the four drugs were able to reduce the clotting of blood significantly. However, Tamoxifene was found to increase the development of womb cancer.
No related posts.
Leave a Reply
Name (required)
Mail (will not be published) (required)
Website
You can use these HTML tags
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>
Notify me of followup comments via e-mail
Notify me of new posts by email.
Most Popular
Categories
- Alcohol
- Allergies
- Alternative Treatments
- Alzheimers
- Asthma
- Autism
- Cancer
- Care for the elderly
- Cosmetic Surgery
- Deafness
- Dental
- Depression
- Diabetes
- Diet
- Drugs
- Eyes
- Fashion
- Fertility
- Fitness
- Fundraising
- General
- Gyms
- Health Products
- Hearing
- Heart disease
- HIV
- Insurance
- Medical Conditions
- Medical News
- Medical Research
- Mental Health
- MRSA
- NHS
- Psoriasis
- Public Health
- Republic
- Skin cancer
- Smoking
- Tuberculosis
- Vitamins
Copyright © 2014 Health Index
Powered by WordPress & the Atahualpa Theme by BytesForAll. Discuss on our WP Forum